{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:52:40Z","timestamp":1785372760119,"version":"3.55.0"},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"American Society of Hematology Minority Hematology Resident Award Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors for all-cause death or CV events post-ACS hospitalization are lacking. We conducted a single-center study of 41 consecutive patients with MPN with ACS hospitalization after MPN diagnosis. After a median follow-up of 80 months after ACS hospitalization, 31 (76%) experienced death or a CV event (myocardial infarction, ischemic stroke, or heart failure hospitalization). After multivariable Cox proportional hazards regression, index ACS within 12 months of MPN diagnosis (HR 3.84, 95% CI 1.44\u201310.19), WBC \u2265 20 K\/\u00b5L (HR 9.10, 95% CI 2.71\u201330.52), JAK2 mutation (HR 3.71, 95% CI 1.22\u201311.22), and prior CVD (HR 2.60, 95% CI 1.12\u20136.08) were associated with increased death or CV events. Further studies are warranted to improve cardiovascular outcomes in this patient population.<\/jats:p>","DOI":"10.3390\/hematolrep15020040","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T02:28:45Z","timestamp":1686104925000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"15","author":[{"given":"Orly","family":"Leiva","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, New York University Langone Health, New York, NY 10016, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P.","family":"Rosovsky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoon","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular Disease in Myeloproliferative Neoplasms","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F) -Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms: A Population-Based Cohort Study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehm031","article-title":"STEMI and NSTEMI: Are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC\/ACC definition (the OPERA registry)","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2012.12.040","article-title":"Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome","volume":"111","author":"Pendyala","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/eurheartj\/ehn112","article-title":"Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy","volume":"29","author":"Morrow","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0002-8703(00)90314-4","article-title":"Neutrophilia and congestive heart failure after acute myocardial infarction","volume":"139","author":"Kyne","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9149(03)00651-9","article-title":"Leukocytosis and adverse hospital outcomes after acute myocardial infarction","volume":"92","author":"Menon","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: A systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv."},{"key":"ref_16","first-page":"e4","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2021.279032","article-title":"Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: A prospective, observational study","volume":"107","author":"Zwicker","year":"2021","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/2\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:49:36Z","timestamp":1760125776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/2\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["hematolrep15020040"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15020040","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}